Dr. Aaron A. Spitz, MD

Dr. Spitz practices at Laguna Hills Infusion - HOPD in Laguna Hills, California.

Dr. Spitz's NPI, 1164487674, was assigned on April 18, 2006. Dr. Spitz graduated from Weill Cornell Medicine in 1992. Dr. Spitz holds California license G79034.

Dr. Spitz's primary practice is Laguna Hills Infusion - HOPD, at 23961 Calle De La Magdalena, Laguna Hills, CA 92653.

Dr. Spitz's primary practice is Laguna Hills Infusion - HOPD in Laguna Hills, California. Dr. Spitz is also affiliated with MemorialCare Saddleback Medical Center. The medical group on file is Orange County Urology Associates. Dmand AI also links Dr. Spitz to 3 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account. Dr. Spitz's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Spitz practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Spitz's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Spitz is board certified in urology by the American Board of Urology. Dmand AI has Dr. Spitz's licenses on file in 2 states: California and New York.

Dmand AI lists bladder disease, enlarged prostate, erectile dysfunction, kidney cysts, kidney removal surgery, kidney stone disease, prostate inflammation or infection and testicular dysfunction among the conditions Dr. Spitz treats.

CMS data shows 2,941 Medicare services from Dr. Spitz across 22 procedure codes in 2024, for 605 Medicare patients. Medicare paid $146,275 for them.

CMS counts 605 Medicare patients who saw Dr. Spitz in 2024. The largest group is 65 to 74, with 263 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 1.37, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Spitz's median patient age at 67, with 10% women.

In 2024, Dr. Spitz wrote 2,949 Medicare Part D claims for 622 patients. 89% of them were for generic drugs. CMS names the drug for 2,838 of them, across 31 drugs with 11 or more claims each, at $433,153 in total drug cost. In 2023, CMS named 2,983 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 92 out of 100 for Dr. Spitz for performance year 2024, reported as part of a group. Dr. Spitz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Spitz as offering telehealth. CMS counts 17 procedures of prostate resection by Dr. Spitz, more than 76% of the clinicians it reports for that procedure.

Dmand AI links 18 papers to Dr. Spitz, published from 2011 to 2021. 2021 was the busiest year, with 5. The most frequent topics are Infertility, Male, Telemedicine and Erectile Dysfunction. Dr. Spitz has published most often in Fertil Steril. Dr. Spitz's most frequent co-authors are Jared M. Bieniek, MD, Robert E. Brannigan, MD and Tung-Chin Hsieh, MD.

Dmand AI links Dr. Spitz to 1 clinical trial. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 175 general payments to Dr. Spitz from 31 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 71% of the total. Endo Pharmaceuticals Inc. paid the most, $84,708.

Dmand AI lists 9 awards for Dr. Spitz, most recently Top Doctors:LA Area in 2013.

Dr. Spitz graduated from Weill Cornell Medicine in 1992.

Dr. Spitz is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.